| Literature DB >> 32354020 |
Jordan Graves1, Jacob Byerly1, Eduardo Priego1, Naren Makkapati1, S Vince Parish1, Brenda Medellin1, Monica Berrondo1.
Abstract
Driven by its successes across domains such as computer vision and natural language processing, deep learning has recently entered the field of biology by aiding in cellular image classification, finding genomic connections, and advancing drug discovery. In drug discovery and protein engineering, a major goal is to design a molecule that will perform a useful function as a therapeutic drug. Typically, the focus has been on small molecules, but new approaches have been developed to apply these same principles of deep learning to biologics, such as antibodies. Here we give a brief background of deep learning as it applies to antibody drug development, and an in-depth explanation of several deep learning algorithms that have been proposed to solve aspects of both protein design in general, and antibody design in particular.Entities:
Keywords: antibody; antigen; binding prediction; deep learning; drug design; drug discovery; epitope mapping; machine learning; neural networks; protein–protein interaction
Year: 2020 PMID: 32354020 PMCID: PMC7344881 DOI: 10.3390/antib9020012
Source DB: PubMed Journal: Antibodies (Basel) ISSN: 2073-4468
Figure 1Schematic of antibody and ribbon diagram of variable region. The heavy chain (H) of the antibody is depicted in dark blue, while the light chain (L) is shown in light blue. Both chains show labels C for constant region and V for variable region. The complementarity-determining region (CDR) is shown as orange loops on the light chain and yellow loops on the heavy chain. On the right, a ribbon diagram of a CDR is shown with light and heavy chain CDR loops highlighted and labeled (PDB: 1A4J).
Figure 2Protein interfaces surface representation. Binding interfaces represented in solid surfaces. At the top, myoglobin (PDB: 1MBN) is shown in purple, with a heme molecule (yellow sticks) bound and the binding pocket in a solid surface. At the bottom left, beta-actin (light gray, top molecule) is shown bound to profilin (wheat, bottom molecule) with their protein–protein interface (PPI) in solid surface (PDB: 2BTF). On the bottom right, a TSH receptor (brick red, top molecule) and antibody (light blue for light chain, dark blue heavy chain, bottom molecule) complex is shown. Only the antibody CDR is highlighted as a solid surface (PDB: 2XWT).
Figure 3A representation of a deep learning neural network. Input layer in blue, output layer in green, and intermediate layers in yellow.
Comparison of several linear B-cell epitope predictors across five different datasets. Results taken from [45].
| DataSet | Tot Residues | Epitope% | System | 75spec | AUC |
|---|---|---|---|---|---|
| SARS | 193 | 63.3 |
| 86.0 | 0.862 |
| BCPred | 80.3 | _ | |||
| ABCPred | 67.9 | 0.648 | |||
| Epitopia | 67.2 | 0.644 | |||
| CBTOPE | 75.6 | 0.602 | |||
| LBtope | 65.8 | 0.758 | |||
| DMN-LBE | 59.1 | 0.561 | |||
| HIV | 2706 | 37.1 |
| 61.4 | 0.683 |
| BepiPred | _ | 0.60 | |||
| ABCPred | 61.2 | 0.55 | |||
| CBTOPE | 60.4 | 0.506 | |||
| LBtope | 61.2 | 0.627 | |||
| DMN-LBE | 63.6 | 0.63 | |||
| Pellequer | 2541 | 37.6 |
| 62.7 | 0.629 |
| LBtope | 60.9 | 0.62 | |||
| DMN-LBE | 62.8 | 0.61 | |||
| AntiJen | 66319 | 1.4 | DRREP | 73.0 | 0.702 |
|
| 74.2 | 0.702 | |||
| DMN-LBE | _ | _ | |||
| SEQ194 | 128180 | 6.6 |
| 75.9 | 0.732 |
| Epitopia | _ | 0.59 | |||
| BEST10 | _ | 0.57 | |||
| BEST16 | _ | 0.57 | |||
| ABCPred | _ | 0.55 | |||
| CBTOPE | _ | 0.52 | |||
| COBEpro | _ | 0.55 | |||
| LBtope | 75.3 | 0.71 | |||
| DMN-LBE | _ | _ |